09.23.25 -- Did Trump Just Create An Antibiotic Supply Chain In The U.S.?

Join us Oct. 9 for the Cell & Gene Therapy session of the Outsourced Pharma Capacity Update and discover leading CDMOs ready to accelerate your development and manufacturing programs. Hear directly from CDMO experts as they showcase their cell and gene therapy capabilities, discuss available capacity, and share opportunities for collaboration. Don’t miss this chance to find the right partner for your project. Save your spot today!

By implementing an efficient characterization strategy, researchers can enhance the consistency of allogeneic cell therapy starting material, ultimately leading to improved clinical outcomes.

See how companies can reduce risk, improve flexibility, and accelerate their time to market by partnering with a single supplier that can handle the entire manufacturing value chain.

This study demonstrates the effect of different promoters and PREs (Post-Regulatory Element) on multiple CAR and transgenic TCR constructs on titer, integration, expression, and in vitro function.

 Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

Learn how delivering a comprehensive CMC package under a single manufacturer can help to minimize the logistical complexity of multiple vendors that leads to major risks for RNA program success.

Review the results obtained for our proprietary HEK293T 2G7 suspension cell line for LVV production by transient transfection in serum-free, chemically-defined and animal component-free media.

Don’t miss this compelling interview with Boro Dropulić, CEO of Caring Cross, on how the cell and gene therapy sector can turn scientific breakthroughs into global health solutions.

Speed up the delivery of cell and gene therapies by adopting streamlined validation and utilizing strategies that reduce timelines and support sustainable, compliant manufacturing pipelines.

Observe how a milestone-driven risk management strategy streamlines cell therapy development, reduces uncertainty, and aligns early decisions with long-term commercialization and regulatory success.

Review an innovative method to fast-tracking AAVs through a platform approach that easily scales as the project progresses to late-stage GMP production and to market.

With over 120 years of combined experience in cell and gene therapies, our team utilizes know-how and process advancements that were established by our founders and builds upon that for our clients.

Discover how lipid nanoparticles revolutionize intracellular drug delivery to enhance RNA vaccines, cell therapies, protein replacement, and gene editing.

Our services include preclinical, CMC release, and clinical testing across our in-house and specialty laboratories. In collaborating with you, we'll tailor a strategy that provides expert support.

Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells.